Janux Therapeutics, Inc. (JANX)
NASDAQ: JANX · Real-Time Price · USD
13.98
+0.14 (1.01%)
At close: Mar 9, 2026, 4:00 PM EDT
13.74
-0.24 (-1.70%)
After-hours: Mar 9, 2026, 5:16 PM EDT
Janux Therapeutics Revenue
In the year 2025, Janux Therapeutics had annual revenue of $10.00M, down -5.55%.
Revenue (ttm)
$10.00M
Revenue Growth
-5.55%
P/S Ratio
83.70
Revenue / Employee
$91,743
Employees
109
Market Cap
850.43M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| MannKind | 348.97M |
| Arvinas | 262.60M |
| Phathom Pharmaceuticals | 175.11M |
| Xencor | 125.58M |
| Arbutus Biopharma | 14.61M |
| Evommune | 13.00M |
| KalVista Pharmaceuticals | 1.43M |
JANX News
- 11 days ago - Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights - Business Wire
- 20 days ago - Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011 - Business Wire
- 6 weeks ago - Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer - Business Wire
- 6 weeks ago - Janux Therapeutics Strikes Bristol Myers Biotech Deal Worth $800 Million - Benzinga
- 6 weeks ago - Janux Therapeutics, Bristol Myers enter up to $850 million deal to develop cancer drug - Reuters
- 6 weeks ago - Janux Therapeutics Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develop a Novel Tumor-Activated Therapeutic for Solid Tumors - Business Wire
- 2 months ago - Janux Therapeutics Provides Program Update on Ongoing Phase 1 JANX008 Study - Business Wire
- 3 months ago - Janux Therapeutics Stock Hits 52-Week Low After Trial Update - Benzinga